Alert detail
LCD L39585: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma — CGS Administrators
What changed
Coverage for risk stratification tests for skin cancer.
Who’s affected: Oncology billing teams · Effective: May 28, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.